Clinical efficacy of Biejiaruangan compound tablets in treatment of primary biliary cirrhosis

• Main Author: HUANG Lingying
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2015-02-01
• Series: Linchuang Gandanbing Zazhi
• Subjects: liver cirrhosis; biliary; Biejiaruangan compound tablets; tauro-ursodeoxycholic acid; treatment outcome
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=6266&ClassID=11415055
• ISSN: 1001-5256; 1001-5256

ObjectiveTo evaluate the clinical efficacy of Biejiaruangan compound tablets in the treatment of primary biliary cirrhosis (PBC). MethodsIn a randomized, double-blind, placebo-controlled study, 56 patients with PBC were collected and equally divided into treatment group and control group. The treatment group was given Biejiaruangan compound tablets (4 pills per dose, 3 doses per day, oral administration) combined with ursodeoxycholic acid (UDCA) tablets (50 mg/pill, 10-15 mg per kg per day). The control group was given placebo (4 pills per dose, 3 doses per day, oral administration) combined with UDCA tablets (50 mg/pill, 10-15 mg per kg per day). All patients were treated for 12 months. Clinical symptoms, PBC-40 scales, liver function ［alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), and total bilirubin (TBil)］, and liver stiffness values in the two groups were evaluated before and after treatment. Comparison of continuous data between the two groups was made by t test, and comparison of categorical data was made by chi-square test. ResultsThe levels of ALT, AST, GGT, ALP, and TBil in the treatment group significantly decreased after 12 months of treatment (t=3.2019, P＜0.01; t=3.0953, P＜0.01; t=3.0279, P＜0.01; t=2.4420, P＜0.05; t=2.1621, P＜0.05). In the control group, only the level of GGT significantly decreased after treatment (t=19981, P＜0.01). The levels of GGT and ALP were significantly lower in the treatment group than in the control group (t=2.0061, P＜0.05; t=2.3106, P＜0.05). The liver stiffness value in the treatment group significantly decreased after treatment (14.37±10.58 vs 1002±5.96 kPa, t=2.1134, P＜0.05). The PBC-40 scales of skin itch, fatigue, and social dimension in the treatment group significantly decreased after treatment for 12 months (t=2.5158, P＜0.05; t=2.1409, P＜0.05; t=3.2441, P＜0.05). There were significant differences in scales of fatigue and social dimension between the two groups after 12 months of treatment (t=3.1491, P＜0.05; t=26287, P＜0.05). ConclusionBiejiaruangan compound tablets can significantly improve liver function, reduce the liver stiffness value, and improve PBC-40 scales of skin itch and fatigue in patients with PBC. This therapy holds promise for widespread clinical application.